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Abstract
B13, one of the immunodominant antigens of Trypanosoma cruzi, is composed of repeats of a 12-amino-acid motif. Using
synthetic peptides, the sequence FGQAAAGDK was previously shown to contain the B13 immunodominant epitope recognized by
chagasic patients sera. To investigate the eﬀects of neighboring sequences in the immunodominance, we tested serum recognition of
two B13 sequences fused to LamB. GDKPSPFGQAAA–LamB and FGQAAAGDKPSP–LamB were recognized, respectively, by
15% and 80% of 80 sera reactive to B13 antigen. Recognition of FGQAAAGDKPSP–LamB was inhibited by AAAGDK-containing
synthetic peptides. FGQAAAGDKPSP–LamB competed with a B13 recombinant protein containing 16.6 repeats for binding to
chagasic antibodies. These results strengthen previous conclusions on the immunodominant epitope of B13 and provide a com-
parison of two methods for epitope mapping.
 2004 Published by Elsevier B.V. on behalf of the Federation of European Microbiological Societies.
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Several pathogenic protozoa, such as Trypanosoma
cruzi, Trypanosoma brucei, Plasmodium and Leishmania,
express many antigens carrying repeated amino-acid
epitopes that are immunodominant in natural infections
[1–3]. Thus, the expression of peptide repeats seems to
be a generalized phenomenon among protozoan para-
sites that evade the host immune system [1,2]. Although
a large number of parasite repeated antigens have been
isolated, little is known on the molecular mechanisms
underlying the immunodominance of the repetitive epi-
topes. Studies on the conformational structure of these* Corresponding author. Tel.: +55-11-5576-4537; fax: +55-11-5571-
6504.
E-mail address: pereiracm@ecb.epm.br (C.M. Pereira).
0378-1097/$22.00  2004 Published by Elsevier B.V. on behalf of the Feder
doi:10.1016/j.femsle.2004.04.040repetitive epitopes are mandatory to better deﬁne the
molecular aspects of immunodominance.
The T. cruzi B13 antigen, located on the surface of
infective trypomastigotes, is composed of arrays of a
tandemly repeated 12-amino-acid motif – P(L)P(S,A)-
P(L)FGQAAA(E)G(A)D(G)K, where residues within
parentheses can be found replacing the preceding resi-
due in diﬀerent repeat copies [4]. B13, puriﬁed as re-
combinant protein from Escherichia coli, has been
shown to present high sensitivity and speciﬁcity in the
serological diagnosis of Chagas disease [4,5]. The char-
acterization of B13 immunodominant epitopes has been
based on the use of synthetic 9-mer peptides, derived
from the B13 sequence, in competitive ELISA with B13
recombinant protein and sera from chagasic patients [6].
This analysis indicated that the peptide FGQAAAGDK
contained the immunodominant epitope of B13 and that
the 7-mer sequence QAAAGDK should be the core ofation of European Microbiological Societies.
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 that epitope [6,7]. Conformational preferences of syn-
thetic peptides bearing the immunodominant epitope of
the B13 antigen have been investigated by our group by
circular dichroism and 1H nuclear magnetic resonance
[8]. The data suggested a correlation between the pro-
pensity of the peptides to adopt a helical conﬁguration
centered in the AAAGDK sequence and their antige-
nicity. Even though such studies thoroughly analyzed
the antigenicity of short synthetic peptides representing
the amino-acid sequences of selected regions of the an-
tigenic B13 protein, they did not provide insights into
how epitopes are recognized in the context of a native
protein antigen. It has been reported that antibody
recognition of B cell epitopes as free synthetic peptides
can diﬀer from that of the same epitopes embedded into
a folded protein [9].
Bacterial surface display techniques based on in-
frame fusion of heterologous sequences to a carrier
protein had initial interest for the development of live
bacterial vaccines. Peptide antigens from a variety of
pathogens have been expressed on the surface of Sal-
monella and E. coli fused to ﬂagellin or outer membrane
proteins, respectively [10–12]. A number of other ap-
plications, including selection of high-aﬃnity antibodies,
production of anti-peptide antibodies, development of
recombinant whole-cell adsorbents and biocatalysts,
cell-based solid-phase reagents for diagnosis and tools
for the study of adhesin–receptor interactions, shows the
versatility of systems to express protein antigens on the
bacterial surface [13–15].
LamB maltoporin, a 421-amino-acid, trimeric, inte-
gral, outer membrane protein of E. coli, has been used
successfully to display foreign peptides on the bacterial
surface [10,15,16]. The X-ray structure of LamB re-
vealed 18 antiparallel b strands connected to each other
on the cell exterior surface by long unstructured loops
[17]. One of these loops, named L4, spanning amino
acids 149–166 has been used as a site for insertions of
several foreign sequences without disruption of the
proper protein structure, localization, or ability to form
trimers [16,18]. LamB can be expressed in high amounts
in E. coli and is easily puriﬁed.
In a previous study, we described the use of the LamB
protein as carrier of heterologous sequences in order to
map the immunodominant B cell epitope of the T. cruzi
JL8 repetitive antigen [19]. Our results showed that fu-
sions to LamB may provide a simple and useful method
to deﬁne and map B cell epitopes, overcoming obstacles
inherent to synthetic peptides, such as insolubility and
conformational variations. The fact that the site for in-
sertions in LamB is part of a nonstructured loop pro-
vides the possibility for the heterologous sequence to
take on a conformation that mimics its own in the native
protein.
In this work, to conﬁrm the conclusions obtained
with synthetic peptides and to extend the results to invivo systems, we have expressed two sequences derived
from B13 (GDKPSPFGQAAA and FGQAAAGD-
KPSP) in the LamB system and the fusion proteins were
tested for antigenicity. The results conﬁrmed previous
conclusions on the primary structure of the immuno-
dominant epitope of B13 and provide a comparison of
this peptide mapping method with data from synthetic
peptide-based mapping.2. Materials and methods
2.1. Bacterial strain and plasmid
The E. coli strain POP6510 (thr leu tonB thi lacYi
recA dex-5 metA supE) and plasmid pAJC264, which
carries the lamB gene under the control of the tac pro-
moter were a kind gift of Dr. M. Hofnung (Institute
Pasteur, Paris, France). The lamB gene in pAJC264
contains a BamHI site for insertions between amino
acids 153 and 154. Luria broth and Luria agar supple-
mented with ampicillin (100 lgml1) were used for
growth of bacteria. The expression of LamB was in-
duced by addition of isopropyl-b-D-thiogalactoside
(IPTG) (103 M) to the cultures at 0.7A600 followed by
an incubation of 4 h.2.2. Synthetic oligonucleotides, fusion proteins and syn-
thetic peptides
Complementary oligonucleotide pairs corresponding
to two diﬀerent sequences of the B13 gene (GenBank
U15616) (Table 1), B13.1 (coding strand 50-gat-
ccaggtgacaaaccatcaccatttggacaggccgctgcaaat) and B13.2
(coding strand 50-gatccatttggacaggccgctgcaggtgacaaa-
ccatcaccaaat), were inserted in the BamHI site of
pAJC264. The 50 end of the coding oligonucleotides
contained a BamHI half site to provide a rapid restric-
tion analysis screen for the plasmids carrying the inser-
tions. Ampicillin-resistant transformants of strain
POP6510 had their plasmids analyzed for the presence
of the insert by digestion with the enzymes BamHI and
NcoI. The insertions were sequenced using a 20-mer
primer complementary to nucleotides located 69 bp
upstream from the BamHI insertion site in the lamB
gene. A glutathione S-transferase (GST) fusion protein
carrying 16.6 repeats of the 12-amino-acid motif of B13
(B13–GST) was also produced in E. coli (GST fusion
system, Pharmacia) [5]. The recombinant protein was
puriﬁed from IPTG-induced E. coli lysates by aﬃnity
chromatography.
Peptides encompassing linear epitopes of B13 antigen
(Table 1) were synthesized by solid-phase Merriﬁeld
‘‘teabag’’ technology from t-Boc derivatives, HPLC
puriﬁed, and checked by mass spectrometry [6,8].
Table 1
Amino-acid sequences derived from B13 inserted in the LamB protein and amino-acid sequences of synthetic peptides used in ELISA
LamB fusion proteins
B13.1 G D K P S P F G Q A A A
B13.2 F G Q A A A G D K P S P
Peptides
pB13 G D K P S L F G Q A A A G D K P S L F
S4 F G Q A A A G D K
S5 Q A A A G D K P S
S3 S L F G Q A A A G
S2 K P S L F G Q A A
S1 G D K P S P L F G Q
pNR N K S A K Q F S L H I M D S Q P D G S
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 2.3. Puriﬁcation of the LamB proteins
Bacterial cultures were grown in 50 ml of LB-ampi-
cillin, harvested, washed in 50 mM Tris–HCl, pH 8.0,
and resuspended in 0.5 ml of 20% sucrose–100 mM
Tris–HCl, pH 8.0. After the addition of 0.1 ml of 0.5 M
EDTA and 0.2 ml of 10 mg ml1 lysozyme, the cell
suspensions were incubated at 37 C for 15 min. Ex-
traction buﬀer (0.5 ml) (2% Triton X-100, 10 mM
MgCl2, 50 mM Tris–HCl, pH 8.0) was added, followed
by incubation at 30 C for 30 min. The cell membrane
fraction was sedimented by centrifugation at 2500g for
10 min and resuspended in 0.3 ml of Laemmli sample
buﬀer. Samples were boiled for 5 min and the proteins
were separated on preparative 10% SDS–PAGE. The
LamB protein was visualized by staining a strip of the
gel with Coomassie blue. The corresponding portion of
the unstained gel was isolated and LamB was eluted by
incubation of the gel slice in 10 ml ddH2O at 4 C for
18 h. The eluted protein was concentrated on Speed
Vac and quantitated by SDS–PAGE using bovine se-
rum albumin as standard.
For immunoblot analysis, proteins were transferred
to nitrocellulose membranes (Hybond-C Extra, Amer-
sham) at 1 A for 2 h using the buﬀer conditions as
previously described [20]. The membranes were blocked
with 5% milk in phosphate-buﬀered saline (PBS) for 1 h
at room temperature, and incubated for 1 h with rabbit
sera raised against a B13–GST recombinant fusion
protein, diluted 1:100. After three washings with 0.05%
Tween 20 in PBS, bound antibodies were detected with
goat anti-rabbit IgG conjugated with peroxidase (Sig-
ma), diluted 1:1000. After incubation for 1 h with the
conjugate and washings in PBS, the bound antibodies
were detected using the 4-chloro naphtol chromogen.
2.4. Sera
Human sera were obtained from patients with
chronic Chagas disease diagnosed by serological and
clinical symptoms. Serological analyses were performed
by indirect immunoﬂuorescence, indirect hemaggluti-nation and ELISA. All the serum samples used in this
work were positive in ELISA with B13-fused to GST.
For the ELISA against recombinant LamB fusion pro-
teins, the sera were absorbed with puriﬁed wild-type
LamB protein (1 lg of protein per ll of serum). Serum
against the GST–B13 fusion protein was raised in New
Zealand female rabbits immunized with the re-
combinant protein puriﬁed as described. The protein (50
lg) was injected subcutaneously with complete Freund’s
adjuvant. After 15 and 30 days from the ﬁrst injection,
50 lg of protein were injected in the presence of in-
complete Freund’s adjuvant. The rabbits were bled 30
days after the third injection.
2.5. Enzyme-linked immunosorbent assay
Microplates (Nunc) were coated with the puriﬁed
recombinant LamB or GST proteins (50 ng/well) diluted
in carbonate buﬀer (15 mM Na2CO3, 35 mM NaHCO3,
pH 9.6) by overnight incubation at 4 C. The wells were
washed three times with PBS-Tween 0.05% and blocked
with 5% milk for 2 h at 37 C. Sera from chagasic pa-
tients (diluted 1:200) were added and the plates were
incubated for 1 h at 37 C. After three washes with PBS-
Tween 0.05%, rabbit anti-human IgG peroxidase-con-
jugate diluted 1:2000 (DAKO) was added and the plates
were incubated for 1 h at 37 C, before development
with O-phenylenediamine (OPD). For competitive
ELISA, the microplates were coated with B13–GST re-
combinant fusion protein (50 ng/well) diluted in car-
bonate buﬀer (15 mM Na2CO3, 35 mM NaHCO3, pH
9.6) at 4 C overnight. The wells were washed three
times with PBS-Tween 0.05% and blocked with 5% milk
for 2 h at 37 C. Sera from chagasic patients (diluted
1:400), incubated previously with diﬀerent concentra-
tions of the B13–LamB fusion proteins, were added and
the plates were processed as above. Competitive inhi-
bition of B13 ELISA was performed as described [6].
Brieﬂy, appropriate dilutions of serum samples (yielding
A492 in the 0.3–0.8 range) were preincubated with the
synthetic peptides (0.2 M) overnight at 4 C. Each se-
rum/peptide mixture was then incubated 1 h at 37 C in
Fig. 1. Expression and puriﬁcation of the B13–LamB fusion proteins.
(a) Immunoblot of whole cell extracts of E. coli expressing the B13.1–
LamB (lane 1) and B13.2–LamB (lane 2) fusion proteins reacted with
an antiserum raised against GST–B13. The strains POP6510 (lane 3)
and POP6510 carrying the lamB gene without insert (LamB) (lane 4)
were used as negative controls. (b) Coomassie blue staining of 10%
240 C.M. Pereira et al. / FEMS Microbiology Letters 235 (2004) 237–242microplates wells previously sensitized with the B13.2–
LamB protein (50 ng/well). The reaction was developed
using an anti-human IgG peroxidase-conjugate with
OPD as chromogenic substrate. The antigenic activity
for each serum/peptide combination was scored as the
percentage inhibition of binding in B13 ELISA, mea-
sured according to the following equation, where the
nonrelated peptide sequence (pNR), derived from the
human T-cell receptor V a chain (TCR V a 13), was
used as a blank [6]:
A492ðserumþ pNRÞ  ½A492ðserumþ test peptideÞ
=½A492ðserumþ pNRÞ  100:
The values of the percentage inhibition were then plot-
ted for each peptide/serum combination.SDS–PAGE of B13.1–LamB (lane 1) and wild type LamB (lane 2)
proteins after elution from preparative gels. Molecular mass standards
are indicated on the left, in kDa.
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 3. Results and discussion
3.1. Expression of the B13 sequences as fusions to LamB
Previous mapping of the antigenic regions of B13
using synthetic peptides suggested that the sequence
FGQAAAGDK contains the immunodominant epitope
[6]. A 12-amino-acid sequence of B13 containing
the potential immunodominant epitope (B13.2 –
FGQAAAGDKPSP) and another sequence in which the
epitope was truncated (B13.1 – GDKPSPFGQAAA)
were inserted between residues 153 and 154 of LamB, in
an unstructured loop known to be exposed on the sur-
face of the protein, facing the cell exterior. For these
constructions, complementary oligonucleotides corre-
sponding to the B13 sequences were ligated into the
BamHI site of the plasmid pAJC264 and the resulting
plasmids were introduced in strain POP6510. The ex-
pression of the two recombinant LamB proteins was
determined by immunoblots of whole cell extracts of
bacteria induced for the expression of the fusion
proteins with IPTG (Fig. 1(a)). The two B13–LamB
proteins were recognized by antisera raised against B13–
GST recombinant fusion proteins as indicated by the
presence of bands with the expected molecular mass of
about 48 kDa (Fig. 1(a)). The recombinant LamB pro-
teins were expressed at the same levels as the wild-type
LamB and were fractionated as outer membrane com-
ponents. B13–LamB fusions and wild-type LamB to be
used in ELISA were further puriﬁed from this prepa-
ration by eluting from the gel (Fig. 1(b)). The yield of
this procedure was about 5 mg of puriﬁed antigen per
liter of culture.B13.1-LamB B13.2-LamB
Fig. 2. Recognition of LamB fusion proteins by chagasic patients sera.
ELISA using panels of sera from 80 chagasic patients, that were pre-
viously shown to recognize the B13 antigen, and 50 non-chagasic
controls. A492 values of individual sera are shown.3.2. Recognition of LamB fusion proteins by human sera
The B13–LamB fusion proteins were tested by ELISA
with a panel of 80 human chronic chagasic sera, whichhad been previously shown to react with a B13–GST
fusion protein [5]. A panel of 52 normal human sera was
used as negative control. Fig. 2 shows the ELISA ab-
sorbance values of all serum samples analyzed. The
B13.2–LamB fusion containing the sequence
FGQAAAGDKPSP was recognized by 80% of the sera
from chagasic patients, assuming a cut oﬀ absorbance
value equal to the mean OD492 of normal sera plus three
standard deviations (SD). On the other hand, the B13.1–
LamB protein was recognized by only 15% of the sera
from chagasic patients.
These results conﬁrm that the major B cell epitope of
B13 antigen is conﬁned to the FGQAAAGDK se-
quence. In fact, truncation of the epitope in the B13.1–
LamB protein drastically reduced recognition by human
chagasic sera.
To determine whether the antibodies that recognize
B13 in chronic chagasic patients’ sera were directed
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Fig. 3. Epitope mapping of the B13 antigen. (a) Competitive ELISA
for B13–GST protein. Human chagasic serum diluted 1:400 was pre-
incubated with B13.2–LamB or B13.1–LamB proteins, in the indicated
amounts (ng), and added to microtiter plate wells previously coated
with B13–GST recombinant fusion protein (50 ng/well). The wild type
LamB protein was used as a negative control. The average A492 values
from duplicate experiments are indicated (b) Competitive inhibition of
the binding of anti-B13 antibodies to B13.2–LamB by synthetic pep-
tides in ELISA. Bars represent the median percentage of inhibition and
standard deviations obtained for ﬁve chagasic sera.
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 mainly to the epitope represented in B13.2, we tested the
ability of B13.2–LamB to inhibit the binding of human
chagasic sera to B13–GST in a competitive ELISA. A
human chagasic serum that showed high A492 readings
against B13–GST was incubated with diﬀerent concen-
trations of B13.1–LamB or B13.2–LamB proteins before
reacting to B13–GST (Fig. 3(a)). B13.2 was capable of
inhibiting the recognition of the B13 antigen by the
human chagasic serum, in a concentration-dependent
manner, giving further support to the hypothesis that
the sequence FGQAAAGDKPSP contains the immu-
nodominant B13 epitope. As expected, B13.1–LamB did
not interfere in the antibody binding to B13–GST.
Synthetic peptides derived from B13 (see Table 1)
were incubated with ﬁve sera from chagasic patients in
competitive ELISA experiments with B13.2–LamB as
the solid-phase antigen. The median percentage inhibi-
tion for peptides pB13, S4 and S5 (all containing the
core of the immunodominant epitope – AAAGDK)
were 87%, 76% and 51%, respectively (Fig. 3(b)). Pep-
tides S3, S2, S1, which do not contain the immuno-
dominant epitope, and pNR, a negative control peptide
derived from the human T-cell receptor V a chain, did
not inhibit the binding of chagasic sera to B13.2–LamB
protein (Fig. 3(b)).It is noteworthy that the B13.2–LamB construct,
which contains a single repeat of the 12-amino-acid
motif, is able to mimic the immunoreactivity of the
whole B13 antigen in which the sequence is repeated
several-fold. In fact, the data here presented indicate
that B13.2–LamB protein is recognized by 80% of the
sera from chagasic patients.
Previous work indicated that the sequence
FGQAAAGDK (peptide S4) carries the immunodomi-
nant epitope of B13 antigen and that the sequence
AAAGDK should be the core of the epitope [6,8].
B13.1–LamB and B13.2–LamB constructs display dif-
ferent antigenic activities, conﬁrming that the residues
ﬂanking the core AAAGDK modulate the interaction of
the human antibodies with B13 antigen. This was also
conﬁrmed by competitive ELISA between the B13.2–
LamB construct and peptides S1, S2 and S3 which
contain truncated forms of the immunodominant B13
epitope. The data also show that peptides pB13, S4 and
S5 display diﬀerent antigenic activities in agreement with
a previous report of our group [8]. In fact, we have
suggested that the distinct antigenic activities of these
peptides correlate with their propensity to adopt a he-
lical conﬁguration centered in the AAAGDK sequence.
It would be of interest to determine the conﬁguration of
the peptides expressed in the loop L4 of LamB.
Altogether, the results shown here clearly provide
further experimental support for the immunodominance
of the peptide FGQAAAGDK of B13. In addition, the
ﬁnding that a single repeat unit of B13 protein, em-
bedded into a foreign protein, can still be signiﬁcantly
recognized by sera from Chagas’disease patients and can
eﬃciently compete with a protein containing multiple
repeats, indicates that the major epitope of native B13
protein is indeed contained in a single repetitive unit.
These results are thus relevant for both the study of
immunodominance in infections by T. cruzi as well as
for further developments in diagnostic tools of Chagas
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